Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 PatientsGlobeNewsWire • 07/29/20
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/28/20
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With SanofiGlobeNewsWire • 06/09/20
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational MedicineGlobeNewsWire • 05/27/20
Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/20
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 PandemicGlobeNewsWire • 04/02/20
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/27/20
Denali Therapeutics Inc. (DNLI) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 02/14/20
Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/07/20
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 02/01/20
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/19
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s WebsiteGlobeNewsWire • 09/04/19
Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease PioneerSeeking Alpha • 06/12/19
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/19